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Amyloidosisisagroupofdisorderscausedbydepositionofmisfoldedproteinsasaggregatesintheextracellular tissuesofthebody,
leading to impairment of organ function. Correct identiﬁcation of the causal amyloid protein is absolutely crucial for clinical man-
agement in order to avoid misdiagnosis and inappropriate, potentially harmful treatment, to assess prognosis and to oﬀer genetic
counsellingifrelevant.Currentdiagnosticmethods,includingantibody-basedamyloidtyping,havelimitedabilitytodetectthefull
range of amyloid forming proteins. Recent investigations into proteomic identiﬁcation of amyloid protein have shown promise.
Thispaperwillreviewthecurrentstateoftheartinproteomicanalysisofamyloidosis,discussthesuitabilityoftechniquesbasedon
the properties of amyloidosis, and further suggest potential areas of development. Establishment of mass spectrometry aided am-
yloid typing procedures in the pathology laboratory will allow accurate amyloidosis diagnosis in a timely manner and greatly facil-
itate clinical management of the disease.
1.Introduction
Amyloidosis is a heterogeneous group of diseases diﬀering in
cause, treatment, and prognosis. Common to this group of
diseases is the mode of pathogenesis [1, 2]. Amylogenic pre-
cursors misfold and assume a pathological conformation
takingonabeta-pleatedsheetﬁbrillarstructure.Aggregation
of these pathological proteins forms amyloid deposits in var-
ious organs eventually leading to organ failure and death.
Over 20 amyloidogenic precursor proteins have been docu-
mented to form amyloid deposits systemically or localise to
speciﬁcorgans[3].Theamyloidogenicpotentialofthesepro-
teins may relate to an acquired (e.g., clonal immunoglobulin
light chain in AL amyloidosis) or inherited (e.g., genetic mu-
tations causing amino acid substitution in hereditary amy-
loidosis) propensity to form a structurally abnormal protein;
proteins with intrinsic amyloidogenic properties which only
becomeevidentwithaging(e.g.,insenilesystemicamyloido-
sis) or chronically high concentrations (e.g., serum amyloid
A protein); or proteolytic cleavage of the protein precursor
(e.g., β-amyloid precursor protein in Alzheimer’s disease).
Treatment and prognosis depend on identifying the
culprit molecule (Table 1). Because of involvement of vital
organs such as the heart and kidneys, early amyloidosis
identiﬁcation and treatment is associated with better prog-
nosis [4]. Treatment aimed at reducing amyloid deposits in-
volves preventing production and aggregation of these pro-
teins. For example, in AL amyloidosis chemotherapy or au-
tologous haematopoietic stem cell transplantation are re-
quired to kill the clonal bone marrow plasma cells that pro-
duce the pathologic immunoglobulin light chain. Such ther-
apies are inappropriate and in fact harmful for other types of
amyloidosis.Similarly,accuratediagnosisofamyloidsubtype
is critical to guide organ transplantation to replace the organ
that manufactures the pathogenic protein in hereditary amy-
loidosis [4–7]. A detailed review of the clinical manifestation
is beyond the scope of this paper, and the readers are referred
to recent excellent reviews [8, 9].
2. CurrentMethods for Diagnosisand
Amyloid Typing
Suspected amyloidosis is conﬁrmed by positive Congo Red
staining, with red-green dichroism/birefringence under po-
larized light microscopy [10]. Typing is currently achieved
by a multidisciplinary diagnostic approach and requires
detailed clinical evaluation combined with immunohisto-
chemical (IHC) studies [11], biochemical tests [12], genetic2 Journal of Biomedicine and Biotechnology
Table 1: Common types of amyloidosis and treatment options [9, 64].
Amyloid
protein1 Precursor Systemic (S) or
localized (L) Organ involvement Aetiology Treatment options
AL Immunoglobulin kappa
or lambda light chain S, L Cardiac, renal, hepatic,
PNS, and soft tissues
Primary or myeloma
associated
Chemotherapy, stem
cell transplant
ATTR Transthyretin S Cardiac, PNS, GIT, CTS Hereditary Liver transplant
ATTR Transthyretin S Cardiac, CTS Senile Supportive care
AA (Apo)serum amyloid A S Renal Secondary to chronic
inﬂammation Control inﬂammation
1Recommended amyloid protein nomenclature includes preﬁx A [3]. PNS: peripheral nervous system; GIT: gastrointestinal tract; CTS: carpal tunnel
syndrome.
studies [1], and sometimes functional imaging [13]. When
applied to amyloid deposits, IHC on formalin-ﬁxed paraﬃn-
embedded (FFPE) tissues often suﬀers from low speciﬁcity
and sensitivity [11, 14]. There are several reasons for this.
Firstly,antibodiesproducedagainstnativeprecursorproteins
are often ineﬀective in detecting aberrantly produced and
misfolded amyloid counterparts. Genetic mutations can also
cause loss of epitope in the amyloid protein. This problem
is exempliﬁed by the over 80 amyloid-causing mutations in
transthyretin. Furthermore, one of the most common amy-
loid precursor proteins is immunoglobulin light chain. Due
to the hypervariable nature of immunoglobulins, antibodies
aregenerallyproducedagainsttheconstantregions,meaning
these antibodies are unresponsive against truncated AL pro-
teins expressing variable regions. Finally, the formalin ﬁxa-
tion process also traps the abundant normal serum protein
counterparts in the tissue sections, a process called “con-
tamination”, causing high nonspeciﬁc background staining
[15].
Since amyloidosis is usually related to an underlying dis-
order or genetic mutation, diagnosis of the primary disease
may help determine the type of amyloid present. Clinically
however, genetic and pathological predisposition does not
always equate to type of amyloidosis and, there is signiﬁcant
overlap between the disease phenotypes of the various amy-
loid subtypes. For example, discovery of a clonal plasma cell
population, which is usually associated with AL amyloidosis,
may actually be an incidental ﬁnding as monoclonal gam-
mopathy of undetermined signiﬁcance is not uncommon in
the elderly [1]. Similarly, while the presence of a family his-
tory is important to diagnose hereditary amyloidosis, a low
penetrance in carriers of the mutation, overlapping involve-
ment of organs usually aﬀected in acquired (AL and AA)
amyloidosis, and failure ofIHC typing to identify the mutant
protein can result in misdiagnosis of hereditary as an ac-
quired amyloidosis [16]. In addition, various atypical cases
have been reported in the literature, and copopulations of
amyloid proteins have been found in amyloid deposits. Fur-
thermore, diﬀerent amyloid subtypes can deposit in diﬀerent
organs in an individual further complicating amyloid typing
and subsequent management [17–21]. These factors illus-
trate the diﬃculty in subtyping amyloidosis which is very
important because correct diagnosis is the key to eﬀective
treatment.
3.CurrentProteomics Technology
Before introduction of protein identiﬁcation by mass spec-
trometry, N-terminal Edman degradation was the method of
choice for protein sequencing [22]. This method involves the
sequential addition of a phenylisothiocyanate (PITC) probe
to and cleavage of the N-terminal amino acid. The released
phenylthiohydantoin (PTH) amino acid is identiﬁed by
HPLC analysis. The process can be repeated to analyse sub-
sequent amino acids, with a limit of approximately 30.
Proteomics studies diﬀer from protein biochemistry
studies with the aim of detecting and measuring the entire
complement of the proteome. This goal required high-
throughput protein identiﬁcation methods. Advent of mod-
ern proteomics technology was shaped by the completion of
the Human Genome Project and development of other ge-
nome databases, together with advances in high-resolution
mass spectrometry. Before considering recent research and
future prospects in using mass spectrometry to identify amy-
loid proteins, it is pertinent to review mass spectrometry-
based protein identiﬁcation techniques and how they relate
to amyloidosis typing.
Two aspects need to be considered in mass spectrometry-
assisted amyloidosis typing: (a) sample source selection and
preparation and (b) mass spectrometry and bioinformatics
analysis.
3.1. Sample Source Selection and Preparation. The amyloid-
causing protein must be isolated from normal tissue proteins
to enable its identiﬁcation. Since amyloidosis can also result
from overproduction of wild-type proteins, direct analysis of
the amyloid deposit is necessary to ensure identiﬁcation of
the causal protein. Analysis of Congo Red-positive regions of
FFPE samples is the most straightforward method. However,
protein recovery from FFPE samples presents several chal-
lenges: the paraﬃn wax must be removed, and the ﬁxation
reversed before the proteins can be extracted with any eﬃ-
ciency. Since archival FFPE blocks are a rich source of clinical
samples, several protocols have been developed to overcome
these issues [23, 24].
Other sources have been suggested including abdominal
adipose tissue [25–27]a n ds e r u m[ 13, 28–30]. In particular,
the possibility of a noninvasive serum-based amyloidosis
diagnostic test is very attractive. The diﬃculty in usingJournal of Biomedicine and Biotechnology 3
serum or normal tissue as a sample is the technical challenge
of separating amyloid protein from normal tissue protein
without the guidance of Congo Red staining. Apart from
immuno-isolation using antibody to the suspected amyloid
protein, currently there is no structural-based method to
separate amyloid ﬁbrils from normal serum or tissue pro-
teins.
Mass spectrometry is a concentration-dependent tech-
nique, where the higher abundance analytes will be prefer-
entially analysed. Hence, apart from samples containing few
proteins, such as amyloid deposit extract, one or more
separation steps need to be performed to ensure depth of
coverage. Proteins can be separated by one- or two-di-
mensional gels or by liquid chromatography (LC). One-di-
mensional sodium dodecyl sulphate polyacrylamide gel elec-
trophoresis (SDS-PAGE) separates proteins by size and is a
simple and robust method for protein separation. Two-di-
mensionalgelelectrophoresis(2DE)allowshigherresolution
of a complex protein mixture. Proteins are ﬁrst separated on
the basis of their charge by isoelectric point focussing (IEF),
and then by size using SDS-PAGE. Analytes are separated
according to physical properties such as charge or hydropho-
bicity. Reverse phase LC has been used to separate amyloid
proteins from other tissue proteins by preferential elution
at 35–45% acetonitrile [11]. Peptide level separation is
generally performed by reverse phase LC using C18 columns
online with an electrospray mass spectrometer.
3.2. Mass Spectrometry and Bioinformatics. Several mass
spectrometry methods are now routinely used for protein
identiﬁcation with standard mass spectrometers readily
available in research facilities. Mass spectrometry measures
the mass of charged (ionized) analyte (protein or peptide),
recorded as a mass-to-charge ratio (m/z). Mass spectrome-
ters are classiﬁed according to their mode of ionization and
the type of mass analyser. There are two main modes of ion-
ization,MALDI(matrix-assistedlaserdesorptionionization)
and ESI (electrospray ionization). Mass analysers can be
divided into two main types, TOF (time-of-ﬂight) and Q
(quadrupole), with ion trap being a subtype of quadrupole
analysers which traps selected ions hence allowing greater
sensitivity. The discussion here will be restricted to mass
spectrometers commonly used in nonspecialist laboratories
as these instruments will be most accessible for clinical
diagnostics.
Mass spectrometric identiﬁcation of proteins is based on
the concept that all naturally occurring mammalian amino
acids (except for the leucine and isoleucine pair) have a
unique mass, and hence each combination of sequences will
correlatewithaspeciﬁcmass.Proteinsmaybeanalysedintact
(“top-down” proteomics) to obtain the mass of the entire
protein. However, since many proteins will have the same
total mass, and due to the current limits in the range of
m/z detection, “bottom-up” proteomics is more commonly
used for protein identiﬁcation. In “bottom-up” proteomics,
proteins are proteolytically cleaved into peptides prior to
mass spectrometry, and protein identities are inferred from
the identiﬁed peptides.
Inhighlypuriﬁedsamples(containing1–5proteins),suf-
ﬁcient information is gained from the masses of the pro-
teolytic peptides to identify the protein(s), a method called
peptidemassﬁngerprinting(PMF)[31–34].InatypicalPMF
experiment, gel-separated proteins are excised and subjected
to in-gel digest with trypsin, which cleaves C-terminal of
arginine and lysine (except before proline). The m/z ratios
of tryptic peptides are then measured to generate a peptide
ﬁngerprint of the protein(s) which were then matched
against in-silico tryptic digest of the entire database using
speciﬁcally designed algorithms. MALDI-TOF is usually the
mass spectrometer used for PMF analysis due to speed and
ease of use. While PMF does not actually provide sequence
information, by further fragmenting selected peptide ions
and detecting the resulting daughter ions in a second mass
analyser, sequence information can be obtained by a similar
spectral matching algorithm. This method is called tandem
massspectrometry(MS/MSortandemMS)[35]andiscom-
monly used with electrospray mass spectrometers, although
MALDI-TOF/TOF instruments are also now widely used.
Protein identiﬁcation both PMF and MS/MS requires
database searching using specialist software and sequence
databases. Since the principle of these methods rely on
matching the experimental spectra to theoretical spectra
generated from a sequence database, it follows that only
sequences within the selected database has a chance of being
“identiﬁed”. De novo MS/MS peptide sequencing without
thereferencetoasequencedatabasecanbeperformedmanu-
ally by correlating the mass diﬀerence between MS/MS peaks
[36]. Understandably, manual interpretation has not gained
popularity with researchers undertaking proteome-wide
studies.Manyalgorithmshavebeendevelopedforautomated
de novo sequencing over the past decade [37–43].
The formalin ﬁxation process introduces many chemical
alterations to the proteins, which reduces the eﬃciency of
protease cleavage and/or alters the mass of the resulting
peptides. These variables must be considered in the bioin-
formatics analysis to ensure accurate protein identiﬁcation.
4. Proteomic Investigationsin
Amyloidosis Typing
Given the importance of identifying the culprit protein in
amyloidosis, recent years have seen collaborative eﬀorts bet-
weencliniciansandproteomicsresearchersintheapplication
of high-resolution mass spectrometry to amyloid identiﬁca-
tion (Table 2).
One stream of studies focused on the serum as a sample,
initially using immune-aﬃnity puriﬁcation to isolate known
amyloid protein followed by mass spectrometers analysis,
with the aim of identifying the mutation [28, 29, 44–47].
The methods developed were translated to clinical assays
[28, 45], however, these methods require antibody of high
speciﬁcity, and some mutations may destroy the antigenic
epitope leading to reduction or loss of antibody binding. In
addition, amyloid proteins may preferentially deposit in tis-
sue leading to low serum levels. Furthermore, genetic muta-
tion is already routinely identiﬁed through DNA sequencing4 Journal of Biomedicine and Biotechnology
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with high accuracy. Recognising the pitfalls of antibody-
based methods, alternative, nonimmune strategies were de-
vised for tissue and/or serum analysis. These include use of
multidimensional HPLC separation [48], SDS-PAGE frac-
tionation then excising region according to predicted size
of the (known) amyloid protein [49] and HPLC separation
following by binding to an activated MALDI surface, a
method termed Surface-Enhanced Laser Desorption Ionisa-
tion (SELDI) [50]. Most of these methods were designed to
detect mutation in known amyloid protein (usually trans-
thyretin) and to measure the relative abundance of mutant
to wild-type proteins.
In order to identify unknown amyloid proteins, an
antibody-freemethodbasedonanalysisoftheactualamyloid
deposit is required. Tissue biopsies are routinely processed
into FFPE samples. FFPE-processed samples have not been
extensively used in proteomics studies due to the potential
chemical alterations and diﬃculty in protein extraction. In
a ne a r l ys t u d y ,M u r p h ye ta l .[ 11]e x t r a c t e dp r o t e i ns a m -
ples from multiple FFPE slides of diﬀerent amyloid types.
Extraction was performed by denaturing the scraped slides
in a solution containing 50mM Tris-HCl, pH8.0, 0.2M
EDTA, and 6.4M guanidine hydrochloride at 37◦Cf o ru p
to 5 days, and sonicating until the solution is clear. Am-
yloid proteins were puriﬁed by HPLC and identiﬁed by
Edman sequencing. Samples that could not be sequenced
were analysed by peptide mass ﬁngerprinting. In a follow-up
study,theauthorsusedasimilarmethod,withtheincubation
time increased to 8–10 days with daily sonication, to ex-
tract amyloid proteins from FFPE slides and abdominal fat
aspirates and adopted de novo sequencing by tandem mass
spectrometry [51]. Although too time consuming as clinical
pathology procedures, these studies demonstrate the poten-
tial for proteomic identiﬁcation of amyloids from FFPE sam-
ples.
Instead of the extensive puriﬁcation steps, a team from
the Mayo Clinic pioneered the use of laser microdissection
(LMD) to capture amyloid deposits from FFPE sections, fol-
lowed by ESI-MS identiﬁcation [52–55]. LMD utilizes clev-
erly designed caps with computer-guided laser to capture
regions of interest from tissue sections [56]. Extraction used
a mild solution containing 10mM Tris, 1mM EDTA,
0.0002%Zwittergent3-16andwasshortenedto90minutesat
98◦C, followed by 60 minutes of sonication. Following tryp-
tic digest, peptides of were analysed with LC-tandem mass
spectrometry. Using a training set of 4 amyloid subtypes
to design an algorithm, Vrana et al. reported greater than
98% speciﬁcity and sensitivity for their assay in detecting
the amyloid subtypes used in training the algorithm [55].
We have successfully extracted proteins from LMD-dissected
amyloid deposits using a commercial FFPE Protein Extrac-
tion Solution (Agilent) with a 10 minute incubation at 95◦C,
followed by 2 hours at 60◦C.
A novel method correlating MS data with tissue loca-
tion is mass spectrometry imaging (MSI). Like traditional
immunohistochemistry for amyloid detection, tissue sec-
tions are mounted on activated glass slides but are processed
by a robotic liquid handler to dispense protease and then
matrix, and analysed using MALDI-TOF with MS imaging
software [57]. This method has the advantage of detecting
amyloidsinsitu,allowingcorrelationtothedeposit.Aproof-
of-concept study used fresh frozen mouse brain tissue to
correlated amyloid β peptide with immunostaining of con-
secutive sections [58]. In a follow-up report, MSI analysis
successfully identiﬁed the amyloid type in a FFPE amyloid
sample that has been preserved for over 100 years [59].
5. Outlook for Proteomics in
Amyloidosis Typing
Although relative few in number, recent studies have aptly
demonstrated feasibility in mass-spectrometry-based amy-
loid typing. Indeed, LMD-MS is currently the gold standard
for amyloid subtyping [4]. A clinically useful assay needs
to be accurate, fast, and suitable for the relevant sample
type. Although highly accurate, LMD is not a fast technique,
requiring 1–1.5 hour per slide even in experienced hands
[56]. After LMD, sample preparation requires a further 1-2
days to undergo ﬁxation reversal, protein denaturation, and
proteolytic digestion.
One possibility is to combine the LMD and MS steps by
using imaging MALDI-MS/MS (MSI-MS/MS). Recent pilot
studies point to the potential for using MSI-MS/MS for
amyloid-type identiﬁcation from FFPE sections [59]. The
lack of protein/peptide separation steps in MSI-MS/MS lim-
i t st h ed e p t ho fp r o t e o m ec o v e r a g ea b l et ob ea c h i e v e di n
this technique. However, this limitation is not a problem for
amyloiddepositswhichcontains1or2majorproteins,which
are the amyloid proteins of interest. Hence the possibility of
directly using Congo Red-stained FFPE section for guided
MSI-MS/MS in amyloid typing is an exciting prospect. Fur-
thermore, this technique is more likely to achieve wide prac-
tical use in clinic as it is much more streamlined and requires
less sample handling compared to LMD-MS. The time-Fur-
thermore steps in LMD-MS include LMD, the extensive
extraction steps and tryptic cleavage. MSI-MS/MS does not
requireLMDorproteinextraction,andthetrypticcleavageis
fasterbecauseitoccursinmuchsmallervolumes(ondroplets
sprayed on the slide). MSI-MS/MS can also be adapted for
the analysis of tissue microarray and fresh frozen tissue sam-
ples of diﬀerent clinical conditions in histopathology. Results
from MSI-MS/MS can be correlated with adjacent tissue sec-
tions analyse by immunohistochemistry to coordinate pro-
tein identity and location. With the possibility to automate
samples preparation, MSI-MS/MS is an attractive technique
for the clinical pathology laboratory.
Another important area of development is bioinformatic
analysis software for de novo peptide sequencing [37–40, 42,
60, 61], and those combining de novo peptide sequencing
(sequence tag) with MS/MS database searching for protein
identiﬁcation [41, 62]. Performance of de novo sequencing
is likely crucial to successful amyloidosis typing due to (1)
high likelihood of mutations and immunoglobulin variable
regions that are not in the sequence database, and (2)
increased likelihood of chemical modiﬁcations due to FFPE
processing. Hence deployment of an accurate de novo
sequencing algorithm with or without MS/MS databaseJournal of Biomedicine and Biotechnology 7
matching should be considered in proteomics analysis of
amyloid deposits.
In conclusion, technical advances in mass spectrometry
and development of bioinformatic algorithms have matured
to bring mass-spectrometry-based amyloidosis typing diag-
nostics.Massspectrometrytechniquesarealreadybeingused
in clinical pathology [63]. The tissue slide sample format of
MSI-MS/MS is a comparable and complementary technique
to immunohistochemistry. With automated samples prepa-
ration and development of diagnostic algorithms, MSI-
MS/MS will be extremely useful for clinical amyloidosis sub-
typing in the near future.
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